Chronic Liver Disease - Yale Medicine Explains
Why It Matters
Accelerating scar‑reversal therapies and expanding viable donor livers could transform treatment pathways, decreasing transplant demand and improving outcomes for millions with chronic liver disease.
Key Takeaways
- •Liver regenerates after injury, but chronic damage leads to scarring.
- •Ongoing repair without resolution causes cirrhosis and end‑stage disease.
- •Liver transplantation uses deceased or living donors; both grafts regenerate.
- •Normothermic machine perfusion expands donor pool by preserving marginal livers.
- •Yale’s research targets inflammation, metabolism, and epithelial biology for new therapies.
Summary
The video explains how the liver’s remarkable regenerative capacity can mask chronic injury, but persistent inflammation eventually leads to fibrosis and cirrhosis, the primary drivers of end‑stage liver disease.
Continuous attempts at repair generate scar tissue that replaces functional parenchyma. When scarring overwhelms regeneration, patients require liver transplantation, which today can be performed with organs from deceased donors or, increasingly, living donors whose partial grafts also regrow to full size.
Yale Medicine highlights normothermic machine perfusion as a breakthrough that keeps donor livers warm, assesses function, and salvages organs previously deemed unusable. The center’s translational programs focus on three intersecting pillars— inflammation, metabolism, and epithelial cell biology— to discover therapies that could interrupt disease progression.
If successful, these advances could reduce the need for transplants, alleviate organ shortages, and lower long‑term healthcare costs associated with chronic liver disease.
Comments
Want to join the conversation?
Loading comments...